HC Wainwright Reiterates “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 56.91% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the company. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. Finally, Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Price Performance

TLX stock traded up $0.97 during mid-day trading on Tuesday, reaching $12.75. 152,459 shares of the company’s stock were exchanged, compared to its average volume of 201,126. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $12.87. The stock’s 50 day moving average is $11.22 and its 200 day moving average is $10.20.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. XY Capital Ltd grew its stake in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $1,731,000. Bank of America Corp DE increased its stake in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC lifted its stake in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pixclara (floretyrosine F 18, or 18F-FET), Telix’s amino-acid PET imaging agent for detecting and characterizing gliomas, a form of brain cancer. The approval covers imaging in both adults and children, creating a significant commercial opportunity in the U.S. and advancing Telix’s radiopharmaceutical pipeline. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: Analysts at Wedbush reaffirmed an Outperform rating and set a $22 price target, signaling substantial potential upside from recent trading levels. The target provides additional investor confidence following the Pixclara approval. Wedbush rating coverage
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, Telix presented an overview of its business and development strategy. The event may improve visibility with institutional healthcare investors, although the supplied transcript does not identify a separate new financial forecast or material corporate announcement. Morgan Stanley Global Healthcare Conference Transcript

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.